Drug Candidate for Schizophrenia, Alzheimer Disease Approved to Initiate Phase 2 Trial in Q2 2024
The candidate also aims to address neurodevelopmental and neurodegenerative disorders such as Parkinson disease and Rett syndrome.
Source: psychiatrictimes.com